Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Trial Profile

Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Leukaemia; Neurofibromatoses; Plexiform neurofibroma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results (n=14) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2017 According to a Daiichi Sankyo Company media release, data from the study will be presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
    • 01 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top